November 22nd, 2019
Saint-Gobain Life Sciences Completes Second of Seven Manufacturing Expansions as Part of Global Facility Expansion Program
LARGO, Fla.--(BUSINESS WIRE)--With construction just ending on its new facility in Largo, Florida, Saint-Gobain Life Sciences celebrates another significant milestone of its €70M global expansion program spanning seven manufacturing sites that will all be completed and operational through the end of 2020.
The 80,000 SF Largo, FL facility will become an additional manufacturing site of Saint-Gobain’s C-Flex® tubing, molded connections and assemblies used in fluid management for biopharmaceutical manufacturing. Saint-Gobain will continue to produce C-Flex® tubing and related product lines at its existing facilities in Clearwater, FL; Charny, France; and Bangalore, India.
The Largo facility is the second of seven ongoing site expansions currently in progress by Saint-Gobain Life Sciences and was preceded by the Bangalore, India site expansion which has been operational since September of 2019.
“This is an exciting time in our business,” said Jean Angus, CEO Saint-Gobain Life Sciences. “This is the execution of a multi-year plan to expand our global manufacturing footprint, which will enhance our ability to service our Life Sciences customers globally with redundant manufacturing facilities. We are increasing the regional availability of our products and our ability to meet customers’ growing demands.”
Saint-Gobain is investing over €70M through a 3-year period to increase manufacturing capacity by expanding or constructing new manufacturing facilities in Beaverton, MI and Largo, FL in the United States; Charny, France; Dublin, Ireland; Bangalore, India; Hangzhou, China; and Songdo, South Korea. “We recognize the responsibility we have to our customers and ultimately, their patients, to increase capacity and localize production, ensuring a reliable, global supply of our products to the Pharmaceutical industry,” said Benjamin Le Quéré, General Manager Saint-Gobain Bioprocess Solutions. All new facilities and expansions will be completed and operational through the end of 2020.
ABOUT SAINT-GOBAIN LIFE SCIENCES
Dedicated to improving the quality of life, Saint-Gobain Life Sciences develops and manufactures high-performance components and integrated solutions that touch a broad range of patient care, from the development of new therapeutic cancer treatments to biopharmaceutical production, on through to intravenous therapies for drug delivery.
Along with material science expertise and collaborative design services, our focus on global quality and regulatory affairs allow us to be the trusted partner to organizations reaching every part of the globe. Combining our technical expertise, global manufacturing capabilities and research and development resources, Saint-Gobain Life Sciences is dedicated to meeting the evolving needs of bioprocess, medical and pharmaceutical customers around the world. Saint-Gobain Life Sciences is part of Compagnie de Saint-Gobain.
Compagnie de Saint-Gobain designs, manufactures and distributes materials and solutions which are key ingredients in the wellbeing of each of us and the future of all. They can be found everywhere in our living places and our daily life: in buildings, transportation, infrastructure and in many industrial applications. They provide comfort, performance and safety while addressing the challenges of sustainable construction, resource efficiency and climate change. Saint-Gobain operates in 68 countries with more than 180,000 employees worldwide. The Company had €41.8 billion in sales in 2018.